7 декабря, 2023

Normal weight does not protect against cardiometabolic diseases

Erkenntnis Persons with «normal» body weight have cardiometabolic problems as often as obese persons. Normal body weight does not exclude an unhealthy metabolic state. The authors advise conducting metabolic screening in people of any weight. Why this matters Metabolic syndrome, which includes insulin resistance, high blood pressure, dyslipidemia and inflammation, can be present in both […]

7 декабря, 2023

Hypertension and cardiovascular events: chlortalidone no better than hydrochlorothiazide

A head-to-head study of these diuretics found that chlortalidone is not superior in the prevention of major adverse cardiovascular events. Knowledge Hypertensive older adults have a similar risk of serious adverse cardiovascular events, regardless of whether they are treated with doses of chlortalidone or hydrochlorothiazide commonly used in clinical practice. Why this matters Early studies […]

5 декабря, 2023

Incidence of scarlet fever and streptococcus group A in more countries

Ministry of Health Incidence of scarlet fever and streptococcus group A in Multiple countries Note on epidemic events abroad At least, five Member States of the European Region have reported to the WHO an increase in cases of invasive group A streptococcus disease (iGAS) and in some cases also ofscarlet fever. An increase in iGAS-related […]

5 декабря, 2023

Hepatitis C update of 12 December 2022 on enrolled patients

AIFA Italian Drug Agency Hepatitis C update of the on enrolled patients The Italian Medicines Agency makes available the weekly update of the data relating to treatments with the new second-generation direct antiviral drugs (DAAs) for the treatment of chronic hepatitis C, collected by the AIFA Monitoring Registers. Published on — Reproduction reserved and for […]

4 декабря, 2023

RKI: Dengue fever among German travellers returning from Ibiza

Core messages On the Balearic island of Ibiza, a cluster of apparently autochthonous denguevirus transmissions occurred between August and October 2022. As the Robert Koch Institute (RKI) with reference to Spanish authorities in its current Epidemiological Bulletin announces, the virus was introduced in the summer of last year by a Spaniard who is believed to […]

4 декабря, 2023

From pre-frailty to frailty, the role of hyperglycemia

The progressive The ageing of the population is causing the number of fragile people to rise and higher, a reality that creates significant challenges for society and health. Preventing, or at least delaying, the transition from pre-frailty, a condition in which the person is still substantially healthy, to frailty, a state that often results in […]

29 ноября, 2023

Acute pulmonary embolism: afterwards often long anxiety and depression

Erkenntnis Up to 2  Years after hospitalization for acute pulmonary embolism (LE), every 5.  Patient with anxiety and/or depression symptoms. Risk factors include history of depression, high-risk PE, low oxygen saturation upon ingestion, and persistent dyspnea. Why this matters The high prevalence of anxiety and depression suggests that careful monitoring of patients’ mental health up to […]

29 ноября, 2023

EMA recommends approval of tremelimumab

The At its meeting in December 2022 a  Recommendation for approval for Tremelimumab (Imjudo, AstraZeneca): The monoclonal antibody should be used in combination with durvalumab as first-line treatment for adults with advanced or unresectable hepatocellular carcinoma. This full text is unfortunately reserved for medical professionals You have reached the maximum number of articles for unregistered visitors […]

20 ноября, 2023

Hepatitis C: adherence is associated with sustained virological response

AIDS Clinical Trials Group (ACTG), the world’s largest HIV research network, announces the publication of «Perspectives on MINMON ACTG 5360 Trial Adherence: A 12-Week Minimal Control Approach of Sofosbuvir/Velpatasvir in the Treatment of Chronic Hepatitis C» in the journal Clinical Infectious Diseases. Perspectives on ACTG 5360 MINMON Trial Adherence: A Minimal 12-Week Follow-up Approach of […]